Intended Audience: All neonatal nurses

NCC Category Codes: NIC3; NNP4

Objectives: Upon completion, learners will be able to:

Outline the pathophysiology of hypoxic ischemic encephalopathy (HIE).
Describe the role of therapeutic hypothermia.
Discuss the pharmacologic options for neuroprotection.

Purpose of this CE Activity:

The purpose of this column is to describe pharmacologic agents being evaluated for neuroprotection after hypoxic-ischemic encephalopathy

Requirements for Completion: The following requirements are necessary for successful completion of this CNE activity.

Access to a computer with an Internet connection
Pass the posttest with a score of 80%
Complete and submit the evaluation for this CNE activity

Accreditation
Provider, Academy of Neonatal Nursing, approved by the California Board of Registered Nursing, Provider #CEP 6261; and Florida Board of Nursing, Provider #FBN 3218, content code 2505.

The Academy of Neonatal Nursing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release Date: November/December 2021
Reviewed on: 10/28/2024
Expiration Date: December 31, 2026

Disclosures:

This CNE activity has been reviewed by the Lead Nurse Planner. It has been determined that the material presented here shows no bias.
The content of this CNE activity has been developed by the planning committee and has been reviewed by the Lead Nurse Planner.

Disclaimer: The Academy of Neonatal Nursing assumes no responsibility or liability for the content presented. Care of the infant should always be individualized and no one source relied upon for information regarding aspects of care. Accredited status does not imply endorsement by ANN, ANA, or the American Nurses Credentialing Center of any commercial products displayed or discussed in conjunction with an educational activity.

Keliana O’Mara PharmD, BCPS

Appearances